Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

tisotumab vedotin

tisotumab vedotin
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Tivdak POWDER FOR INJECTION, INTRAVENOUS 40 mg/vial      
Comments:

Restricted to oncology for use in outpatient setting. 

Reviewed: February 2023 (Tivdak)

Spotlight Tisotumab Vedotin (Tivdak)

Last updated: Apr. 17, 2023






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved